|Rigel to Present at Keystone Symposia Conference|
Session: Workshop 2: New Therapeutic Approaches to MS
Presentation Title: The orally bioavailable Protein Kinase C Inhibitor RGE-80 can abrogate EAE disease induction and ameliorates disease in a therapeutic setting
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.